Anti-KDR antibody

Cat.#: 142780

Special Price 145.2 USD

Availability: In Stock
- +

Add to cart to get an online quotation

Product Information

  • Product Name
    Anti-KDR antibody
  • Documents
  • Description
    Rabbit Monoclonal to Mouse KDR
  • Tested applications
  • Species reactivity
    Mouse VEGFR2 / Flk-1 / CD309 / KDR
  • Alternative names
    FLK1 antibody; CD309 antibody; VEGFR antibody; VEGFR2 antibody; Flk1 antibody; Ly73 antibody; Flk-1 antibody; Krd-1 antibody; VEGFR2 antibody; VEGFR-2 antibody; sVEGFR-2 antibody; 6130401C07 antibody; Flk-1 antibody; 6130401C07 antibody; CD309 antibody; Flk1 antibody; FLK1 antibody; Flk-1 antibody; KDR antibody; kdr antibody; Krd-1 antibody; Ly73 antibody; sVEGFR-2 antibody; VEGFR antibody; VEGFR2 antibody; VEGFR2 antibody; VEGFR-2 antibody
  • Immunogen
  • Isotype
    Rabbit IgG
  • Preparation
    This antibody was obtained from a rabbit immunized with purified, recombinant Mouse VEGFR2 / Flk-1 / CD309 / KDR and conjugated with APC under optimum conditions, the unreacted APC was removed.
  • Clonality
  • Formulation
    Aqueous solution containing 0.5% BSA and 0.09% sodium azide
  • Storage instructions
    This antibody is stable for 12 months from date of receipt when stored at 2℃-8℃. Protected from prolonged exposure to light. Do not freeze !
    Sodium azide is toxic to cells and should be disposed of properly. Flush with large volumes of water during disposal.
  • Applications
  • Validations

    VEGFR2 / Flk-1 / CD309 / KDR Antibody (APC), Rabbit MAb, Flow Cytometry

    VEGFR2 / Flk-1 / CD309 / KDR Antibody (APC), Rabbit MAb, Flow Cytometry

  • Background
    VEGFR2, also called as KDR or Flk-1, is identified as the receptor for VEGF and VEGFC and an early marker for endothelial cell progenitors, whose expression is restricted to endothelial cells in vivo. VEGFR2 was shown to be the primary signal transducer for angiogenesis and the development of pathological conditions such as cancer and diabetic retinopathy. It has been shown that VEGFR2 is expressed mainly in the endothelial cells, and the expression is upregulated in the tumor vasculature. Thus the inhibition of VEGFR2 activity and its downstream signaling are important targets for the treatment of diseases involving angiogenesis. VEGFR2 transduces the major signals for angiogenesis via its strong tyrosine kinase activity. However, unlike other representative tyrosine kinase receptors, VEGFR2 does not use the Ras pathway as a major downstream signaling but rather uses the phospholipase C-protein kinase C pathway to signal mitogen-activated protein (MAP)-kinase activation and DNA synthesis. VEGFR2 is a direct and major signal transducer for pathological angiogenesis, including cancer and diabetic retinopathy, in cooperation with many other signaling partners; thus, VEGFR2 and its downstream signaling appear to be critical targets for the suppression of these diseases. VEGF and VEGFR2-mediated survival signaling is critical to endothelial cell survival, maintenance of the vasculature and alveolar structure and regeneration of lung tissue. Reduced VEGF and VEGFR2 expression in emphysematous lungs has been linked to increased endothelial cell death and vascular regression.Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy